Looney Lab
Therapeutic Targeting of Senescent Cells in Lupus
Targeting senescent cells in patients with lupus presents a potential novel approach to disease management and improved clinical outcomes. While it is known that lupus patients possess cells with a senescence-like phenotype, it is unknown whether these cells would respond to available senolytic drugs. Studying the effects of these drugs in vitro using patient and lupus mouse model samples will further fundamental insights into the potential role of senolytic drugs in the treatment of lupus.
![Richard John Looney, M.D.](http://urmc.rochester.edu/ecv_binary/faculty/generated/profile_web/1683.jpg)
Richard John Looney, M.D.
Principal Investigator
Publications
View All Publications- A Phenotypically Distinct Human Th2 Cell Subpopulation Is Associated With Development of Allergic Disorders in Infancy.; Allergy. 2025 Feb 03.
- The pace of life for forest trees.; Science (New York, N.Y.); Vol 386(6717), pp. 92-98. 2024 Oct 03.
- Factors associated with the choice of treatment for coronoid fractures.; The bone & joint journal; Vol 106-B(10), pp. 1150-1157. 2024 Oct 01.
- Linking head and heart health: the association between psychiatric outcomes for patients with major depressive disorder and myocardial ischemia - a systematic review.; Expert review of cardiovascular therapy. 2024 Oct 01.
January 6, 2025
Jennifer Anolik Named Chief of Allergy, Immunology and Rheumatology Division
December 11, 2024
AIR Faculty Shine at ACR Meeting
October 4, 2024
Dr. Jennifer Anolik Delivers Keynote Address
August 5, 2024
Katherine Escalera-Rivera Receives Awards
June 13, 2024
Drs. Korman and Garcia-Henandez Receive University Research Award
Contact Us
Looney Lab
601 Elmwood Ave/Box 695
Rochester, NY 14642